MedPath

Chemotherapy and Radiotherapy, given either together or sequentially, before surgery followed by surgery in operable cancer of gallbladder patients: A pilot study

Phase 2
Completed
Conditions
Health Condition 1: null- patients with operable carcinoma of Gall Bladder
Registration Number
CTRI/2011/12/002264
Lead Sponsor
All India Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
16
Inclusion Criteria

a) Subjects with FNAC-proven Gall bladder adenocarcinoma (up to operable stage IVA) which is potentially resectable by preoperative imaging

b) Performance status ECOG-1&2

c) Normal renal, hepatic, and hematologic function at the time of enrolment

d) Age 18-65 years

Exclusion Criteria

a) Patient refusal

b) Poor performance status (ECOG â?? 3&4)

c) Major co-morbid conditions like cirrhosis, renal failure, uncontrolled hypertension or cardiac failure -

d) Subjects who have received chemotherapy within 12 months prior to study entry.

e) Prior use of radiotherapy.

f) Subjects who have undergone previous surgery on gall bladder/biliary tree.

g) Any evidence of metastasis to distant organs (liver, lung, peritoneum).

h) Non-contiguous liver metastasis (M1 disease).

i) Major vascular involvement such as proper hepatic artery involvement and main portal vein involvement (T4 â?? inoperable disease).

j) Periaortic, Pericaval, Superior mesenteric artery and/or Celiac artery lymph node involvement (N2 disease) â?? confirmed by FNAC.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ability to achieve surgical resection <br/ ><br>Radiological response <br/ ><br> <br/ ><br>Timepoint: Ability to achieve surgical resection <br/ ><br>Radiological response <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Pathological response <br/ ><br>Toxicity <br/ ><br>Overall survival (OS) <br/ ><br>Timepoint: toxicity will be noted during and after chemoradiation, pathological response on histopathological examination of the resected specimen and OS at the end of two years
© Copyright 2025. All Rights Reserved by MedPath